Impact of Iron Deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction.

Back

HFA Premium Access

Impact of Iron Deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction.

Session: Rapid Fire 2 - Comorbodities

Topic: Anaemia and iron deficiency

Speaker: Doctor P. Martens (Genk, BE)

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Congress Presentation

About the speaker

Doctor Pieter Martens

Ziekenhuis Oost Limburg, Genk (Belgium)

1 presentation

0 follower

9 more presentations in this session

Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement

Speaker: Professor D. Adams (Le Kremlin-Bicetre Cedex, FR)

Heart failure and inflammation-related biomarkers as predictors of new onset diabetes in the general population

Speaker: Doctor N. Suthahar (Rotterdam, NL)

Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- versus post-capillary pulmonary hypertension.

Speaker: Mr T. Gorter (Groningen, NL)

Definition of iron deficiency based on the gold standard of bone marrow iron staining and treatment effect of ferric carboxymaltose in heart failure patients

Speaker: Mr N. Grote Beverborg (Groningen, NL)

Circulating miRNAs as biomarkers for familial dilated cardiomyopathy

Speaker: Doctor D. De Gonzalo Calvo (Barcelona, ES)

Access

Abstract

Access the full session

Rapid Fire 2 - Comorbodities

Speakers: Doctor P. Martens, Professor D. Adams, Doctor N. Suthahar, Mr T. Gorter, Mr N. Grote Beverborg...

Access

About the event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

Sessions Presentations

Congress

Impact of Iron Deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction.

About the speaker

Doctor Pieter Martens

9 more presentations in this session

Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement

Heart failure and inflammation-related biomarkers as predictors of new onset diabetes in the general population

Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- versus post-capillary pulmonary hypertension.

Definition of iron deficiency based on the gold standard of bone marrow iron staining and treatment effect of ferric carboxymaltose in heart failure patients

Circulating miRNAs as biomarkers for familial dilated cardiomyopathy

Access the full session

Rapid Fire 2 - Comorbodities

About the event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

ESC 365 is supported by